Article Text

Download PDFPDF
Positron emission tomography imaging in cardiovascular disease
  1. Jason M Tarkin1,
  2. Andrej Ćorović1,
  3. Christopher Wall1,
  4. Deepa Gopalan2,
  5. James HF Rudd1
  1. 1 Division of Cardiovascular Medicine, University of Cambridge, Cambridge, UK
  2. 2 Radiology, Cambridge University Hospitals NHS Foundation Trust, Cambridge, Cambridgeshire, UK
  1. Correspondence to Dr Jason M Tarkin, Division of Cardiovascular Medicine, University of Cambridge, Cambridge CB2 2QQ, UK; jt545{at}


Positron emission tomography (PET) imaging is useful in cardiovascular disease across several areas, from assessment of myocardial perfusion and viability, to highlighting atherosclerotic plaque activity and measuring the extent of cardiac innervation in heart failure. Other important roles of PET have emerged in prosthetic valve endocarditis, implanted device infection, infiltrative cardiomyopathies, aortic stenosis and cardio-oncology. Advances in scanner technology, including hybrid PET/MRI and total body PET imaging, as well as the development of novel PET tracers and cardiac-specific postprocessing techniques using artificial intelligence will undoubtedly continue to progress the field.

  • advanced cardiac imaging
  • nuclear cardiac imaging
  • positron emission tomographic (PET) imaging
  • chronic coronary disease
  • systemic inflammatory diseases

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.


  • Twitter @jmtarkin, @jhfrudd

  • Contributors JMT, AC and CW drafted the manuscript. JMT, DG and JHFR reviewed and edited the manuscript. All authors contributed to its scientific content. JMT and JHFR are responsible for its overall content as guarantors.

  • Funding JMT is supported by a Wellcome Trust Clinical Research Career Development Fellowship (211100/Z/18/Z), the National Institute for Health Research (NIHR) Imperial Biomedical Research Centre (BRC) and the Cambridge British Heart Foundation (BHF) Centre for Research Excellence. JHFR is part-supported by the NIHR Cambridge BRC, the BHF, the Higher Education Funding Council for England, the Engineering and Physical Sciences Research Council and the Wellcome Trust.

  • Competing interests None declared.

  • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

  • Patient consent for publication Not required.

  • Provenance and peer review Commissioned; externally peer reviewed.